Profile cover photo
Profile photo
Biotechgate
50 followers -
Biotechgate - your source for life sciences company information
Biotechgate - your source for life sciences company information

50 followers
About
Biotechgate's posts

Post has attachment
Come and see us next week at JP Morgan and Biotech Showcase in San Francisco http://www.ebdgroup.com/bts/index.php

Post has attachment
We are joining Genesis Conference taking place tomorrow 12th Dec. If you are attending, please feel free to send us a meeting request. Alan Jones is looking forward to meeting you in London!
http://www.genesisconference.com

Post has attachment
Biotechgate's global life science map is available now - browse the map and explore the global Biotech, Pharma and Medtech landscape:

http://biotechgate.com/gate/v3/companies.php?info=global_map

European financing in biotech surpasses again the USD 100 M mark:

After weak August and September months, October has seen a come-back in the number and value of financing rounds for biotech (Therapeutics and Diagnostics). In Europe the total financing was above USD 100 M for the 4th time in the last 12 months, while the US was back to the level of July investments, the 4th largest in the last 12 months.

Download and read the complete November Biotech Financing Summary: http://www.biotechgate.com/services/v3/statistics-vcdeal

Post has attachment
Biotech Financing Summary October 2013 is available now:

Financing in biotech dropped by 29% in September compared to August 2013. The US contributed mostly to the financing of this month, with 88% share and a financing value of USD 309 M.

http://www.biotechgate.com/services/v3/statistics-vcdeal

We are preparing for the Bio-Europe conference in Vienna. If you are attending as well, schedule a meeting with us or come by and see us at our booth "Venture Valuation / Biotechgate" (No. 11) and try some Swiss chocolate!

Post has attachment
Future of Life Sciences Financing in Europe:

In the biotechnology industry characterized by high-risk and high-return, investments are extremely carefully selected only for the most high value projects. The following article by Dr. Frei provides valuable insights in multiple aspects of life sciences financing, from private and public financing trends to new investment models to partnerships with pharma.

http://hornonline.com/books/life_science_sweden/ebook.html#240

Post has attachment
Drug dealers: $20 trillion of in-licensing payments:

Over the last 17 years, the pharmaceutical industry paid over $20 trillion for drug in-licensing, and the upfront price for these in-licensing deals continues to increase. What are the licensing trends and how do they vary by therapeutic areas? Dr. Patrik Frei and Prof. Kumlesh K. Dev clarify these questions in the following article.

http://www.sciencedirect.com/science/article/pii/S1359644613002766

Post has attachment

Post has attachment
For Life Sciences companies it has never been easy selecting a location for HQs, shared services centers, manufacturing or R+D operations in Europe. A huge variety of factors must be taken into consideration. Venture Valuation, together with KPMG has analyzed the key decision factors relevant to site selection in Europe.
Download the full report at:
http://resourcecenter.venturevaluation.com/2013/10/selecting-a-european-location-for-life-sciences-activities/#sthash.v0df1nDH.DdJg6yop.dpbs
Wait while more posts are being loaded